Prof. Xing Zhang 张星
Chief Physician, Professor
Department of Medical Oncology, Sun Yat-sen University Cancer Center, Guangzhou
Public profile Compiled from public listings and PubMed. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionClinical focus: Medical treatment for bone and soft tissue sarcomas, kidney cancer, and melanoma. Immunotherapy and molecular targeted drug therapy for solid tumors.
Dr. Zhang holds a medical doctorate from Sun Yat-sen University of Medical Sciences (2004) and trained at Boston University School of Medicine (2001–2003). Dr. Zhang is Director of the Melanoma and Sarcoma Medical Ward and Director of the Biological Therapy Center at Sun Yat-sen University Cancer Center.
Professional roles
- Member, Sarcoma Professional Committee, China Anti-Cancer Association
- Deputy Leader, Chemoradiotherapy Group, Sarcoma Professional Committee, China Anti-Cancer Association
- Member, Soft Tissue Group, Sarcoma Professional Committee, China Anti-Cancer Association
- Standing Committee Member, Bone Tumor Physicians Branch, Guangdong Medical Doctor Association
Name order: in Chinese the family name comes first (Zhang Xing). Papers usually list the name as Xing Zhang or Zhang X.
Selected publications
90 papers on PubMed matched by name and affiliation; 26 as first or senior author since 2016. Most recent first- or senior-author papers:
- Clin Cancer Res, 2026 (first author): Long-term Results of Multiantigen Stimulated Cell Therapy I, Alone or in Combination with Chemotherapy, as First-line Maintenance Therapy in Advanced Sarcoma: A Multicenter, Phase I Trial. PubMed 42545754
- Eur J Cancer, 2026 (senior author): Anlotinib plus toripalimab in patients with advanced bone and soft tissue sarcomas including ultra-rare sarcomas: A multicenter, single-arm, phase 2 trial. PubMed 42258994
- Ann Surg Oncol, 2025 (first author): Comparison of Transoral Endoscopic Thyroidectomy via the Vestibular Approach and Conventional Open Thyroidectomy for Papillary Thyroid Carcinoma: A Propensity Score-Matched Analysis. PubMed 40608171
- BMC Cancer, 2025 (senior author): The efficacy and safety of gemcitabine and docetaxel in pseudomyogenic hemangioendothelioma: a multi-center experience. PubMed 40597841
- J Immunother Cancer, 2024 (senior author): Neoadjuvant immunotherapy in the evolving landscape of sarcoma treatment. PubMed 39581705
- Adv Sci (Weinh), 2024 (senior author): Targeting KIFC1 Promotes Senescence in Soft Tissue Sarcoma via FXR1-Dependent Regulation of MAD2L1 mRNA Stability. PubMed 39387242
- Cancer Gene Ther, 2024 (senior author): FGFR4-specific CAR-T cells with inducible caspase-9 suicide gene as an approach to treat rhabdomyosarcoma. PubMed 39183354
- EClinicalMedicine, 2023 (senior author): Anlotinib as a maintenance treatment for advanced soft tissue sarcoma after first-line chemotherapy (ALTER-S006): a multicentre, open-label, single-arm, phase 2 trial. PubMed 37767191
See the full PubMed search. Automatic matching can miss papers or include a namesake at the same hospital. This name is shared by other researchers, so we checked that most papers list this doctor's hospital and department.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and write a treatment plan with a cost estimate.
Get a specialist opinion